Clal Biotechnology Industries Ltd. (TLV:CBI)

TLV:CBI Balance Sheet

Financials in millions ILS. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1.59	1.69	3.95	5.73	7.44	53.05
Trading Asset Securities	-	-	1.06	7.63	5.44	-
Cash & Short-Term Investments	1.59	1.69	5.01	13.36	12.89	53.05
Cash Growth	-0.93%	-66.29%	-62.48%	3.65%	-75.71%	-71.56%
Accounts Receivable	-	-	-	-	-	5.53
Other Receivables	1.81	-	-	0.02	0.65	1.9
Receivables	1.81	-	-	0.02	0.65	7.44
Inventory	-	-	-	-	-	3.73
Prepaid Expenses	-	0.18	0.28	0.82	2.59	2.68
Other Current Assets	-	0.58	0.51	0.49	0.52	10.71
Total Current Assets	3.4	2.46	5.8	14.69	16.64	77.61
Property, Plant & Equipment	0.45	1.35	1.53	4.73	5.09	18.06
Long-Term Investments	28.76	37.84	60.14	138.22	155.69	127.83
Other Intangible Assets	-	-	-	-	-	215.78
Other Long-Term Assets	-	0.19	0.22	0.75	5.28	5.63
Total Assets	32.61	41.83	67.69	158.39	182.69	444.92

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	-	-	-	-	-	14.6
Accrued Expenses	-	0.78	0.58	1.16	1.01	8.29
Current Portion of Long-Term Debt	15.83	16.19	19.17	4.97	-	6.24
Current Portion of Leases	-	0.17	0.15	0.47	1.85	2.43
Current Unearned Revenue	-	-	-	-	-	2.37
Other Current Liabilities	1.28	0.42	0.1	0.07	0.05	1.72
Total Current Liabilities	17.11	17.56	20	6.66	2.91	35.65
Long-Term Debt	-	-	-	25.97	27.39	35.86
Long-Term Leases	0.43	1.4	1.53	4.35	7.49	9.25
Long-Term Unearned Revenue	-	-	-	-	-	24.52
Other Long-Term Liabilities	-	-	-	-	-	1.26
Total Liabilities	17.54	18.95	21.52	36.98	37.79	106.55

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	1.61	1.61	1.61	1.61	1.61	1.61
Additional Paid-In Capital	1,311	1,311	1,297	1,296	1,296	1,295
Retained Earnings	-1,414	-1,408	-1,394	-1,332	-1,301	-1,239
Treasury Stock	-10	-10	-10	-10	-10	-10
Comprehensive Income & Other	123.49	125.02	142.64	143.76	139.37	125.29
Total Common Equity	12.78	20.2	36.63	99.36	126.03	172.59
Minority Interest	2.29	2.68	9.53	22.05	18.87	165.78
Shareholders' Equity	15.07	22.88	46.17	121.41	144.9	338.37
Total Liabilities & Equity	32.61	41.83	67.69	158.39	182.69	444.92

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	16.26	17.76	20.84	35.76	36.73	53.78
Net Cash (Debt)	-14.67	-16.07	-15.83	-22.4	-23.85	-0.73
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.09	-0.10	-0.10	-0.14	-0.15	-0.00
Filing Date Shares Outstanding	147.25	156.85	156.85	156.85	156.85	156.85
Total Common Shares Outstanding	147.25	156.85	156.85	156.85	156.85	156.85
Working Capital	-13.71	-15.1	-14.2	8.03	13.73	41.96
Book Value Per Share	0.09	0.13	0.23	0.63	0.80	1.10
Tangible Book Value	12.78	20.2	36.63	99.36	126.03	-43.19
Tangible Book Value Per Share	0.09	0.13	0.23	0.63	0.80	-0.28

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 22, 2026

Data Sources Report a data error